Psmd2-flox Mouse
一般名
Psmd2-flox
製品ID
S-CKO-06168
背景情報
C57BL/6JCya
系統ID
CKOCMP-21762-Psmd2-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Psmd2-flox Mouse（カタログ番号S-CKO-06168）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Psmd2-flox
系統ID
CKOCMP-21762-Psmd2-B6J-VA
遺伝子名
製品ID
S-CKO-06168
遺伝子別名
Tex190, TEG-190, 9430095H01Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 16
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000007212
NCBIトランスクリプトID
NM_134101
ターゲット領域
Exon 4~8
有効領域の大きさ
~2.4 kb
遺伝子研究の概要
Psmd2, encoding 26S proteasome non-ATPase regulatory subunit 2, is a key component of the ubiquitin-proteasome system. This system is crucial for regulating intracellular protein levels, and thus Psmd2 is involved in multiple cellular processes like protein homeostasis. It has been associated with pathways such as the cell cycle, antigen processing and presentation, JAK-STAT, Toll-like receptor, P53 and MAPK signaling pathways [1].
In various cancers, Psmd2 shows oncogenic properties. In bladder cancer, its overexpression promotes cancer progression and is correlated with immune infiltration, with high Psmd2 predicting unfavorable overall survival [1]. In esophageal squamous cell carcinoma, it contributes to cancer progression by repressing autophagy through activating the mTOR pathway via upregulating ASS1 [2]. In lung adenocarcinoma, upregulation of Psmd2 is linked to poor prognosis and immune infiltration, and it has a high mutation frequency [3]. In renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors, Psmd2 overexpression is related to resistance and decreased progression-free survival, along with changes in immune cell infiltration [4]. In nasopharyngeal carcinoma, DNAJA4 suppresses metastasis via Psmd2-mediated MYH9 degradation [5]. In breast cancer, RACK1 enhances β-catenin stability by competitively inhibiting its binding to Psmd2 [6]. In HepG2 cells, Psmd2 promotes proliferation by modulating lipid droplet metabolism [7]. In breast cancer cells, Psmd2 regulates cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation [8].
In conclusion, Psmd2 plays significant roles in multiple biological processes, especially in cancer-related functions. Its overexpression in various cancers promotes tumor progression, affects immune infiltration, and is associated with poor prognosis. The study of Psmd2 using in vivo models helps in understanding its role in disease development, potentially providing new therapeutic targets for cancer treatment.
References：
1. Wang, Song, Wang, He, Zhu, Shaoxing, Wang, Zongping. 2022. PSMD2 promotes the progression of bladder cancer and is correlated with immune infiltration. In Frontiers in oncology, 12, 1058506. doi:10.3389/fonc.2022.1058506. https://pubmed.ncbi.nlm.nih.gov/36505799/
2. Liu, Yachen, Wu, Meng, Xu, Shuxiang, Xu, Yang, Yu, Lili. 2023. PSMD2 contributes to the progression of esophageal squamous cell carcinoma by repressing autophagy. In Cell & bioscience, 13, 67. doi:10.1186/s13578-023-01016-4. https://pubmed.ncbi.nlm.nih.gov/36998052/
3. Zhao, Huihui, Lu, Guojun. 2022. Prognostic Implication and Immunological Role of PSMD2 in Lung Adenocarcinoma. In Frontiers in genetics, 13, 905581. doi:10.3389/fgene.2022.905581. https://pubmed.ncbi.nlm.nih.gov/35754829/
4. Xu, Xianglai, Wang, Jiahao, Wang, Ying, Wang, Jiajun, Guo, Jianming. 2024. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. In Cellular oncology (Dordrecht, Netherlands), 47, 1943-1956. doi:10.1007/s13402-024-00977-z. https://pubmed.ncbi.nlm.nih.gov/39222176/
5. Zhang, Qun, Feng, Ping, Zhu, Xun-Hua, He, Shi-Wei, Li, Ying-Qing. 2023. DNAJA4 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma via PSMD2-mediated MYH9 degradation. In Cell death & disease, 14, 697. doi:10.1038/s41419-023-06225-w. https://pubmed.ncbi.nlm.nih.gov/37875476/
6. Tian, Ruinan, Tian, Jianfei, Zuo, Xiaoyan, Niu, Ruifang, Zhang, Fei. 2023. RACK1 facilitates breast cancer progression by competitively inhibiting the binding of β-catenin to PSMD2 and enhancing the stability of β-catenin. In Cell death & disease, 14, 685. doi:10.1038/s41419-023-06191-3. https://pubmed.ncbi.nlm.nih.gov/37848434/
7. Tan, Yanjie, Jin, Yi, Wu, Xiang, Ren, Zhuqing. 2019. PSMD1 and PSMD2 regulate HepG2 cell proliferation and apoptosis via modulating cellular lipid droplet metabolism. In BMC molecular biology, 20, 24. doi:10.1186/s12867-019-0141-z. https://pubmed.ncbi.nlm.nih.gov/31703613/
8. Li, Yunhai, Huang, Jing, Zeng, Beilei, Li, Hongzhong, Ren, Guosheng. 2018. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. In Cancer letters, 430, 109-122. doi:10.1016/j.canlet.2018.05.018. https://pubmed.ncbi.nlm.nih.gov/29777785/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。